- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Vivian Bykerk, MD: New Treatments in Inflammatory Disease
Vivian Bykerk, MD, associate attending rheumatologist at HSS, associate professor of medicine at Weill Cornell Medical College discusses new treatments in inflammatory disease.
Transcript
What are some new directions in treating inflammatory diseases that you’re particularly excited about?
So, the first, I guess, and it’s not that new, is early diagnosis. It’s a way to classify the disease sooner than later, having a blood test to be able to do so in a number of people, though not all. Also, part of it is having people understand that the expectation is to get people into remission in the first year, and then, keep them there, as sort of new standards and new guidelines. Another part of it is the translational side of it. There’s a huge effort to now try and understand how the tissue in the rheumatoid joint is functioning in terms of cell-cell interactions, and sending things in and out of the blood to get a new understanding of how the tissue functions to perpetuate the disease and even start the disease. We don’t think it starts in the joint. We think it starts in the mucosa and something travels to the joint, but we don’t know why. And then a whole interaction of cells comes, and they have a party, basically, and they start to work with each other to build what is more like a benign tumor in the joint, and that, in and of itself, is very destructive.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
